STOCKHOLM (Reuters) – Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 currently totals around 2.40 billion crowns ($340 million), including previously announced deferred revenue. The World Health Organisation in August declared mpox a global public health emergency for the second time in […]
STOCKHOLM (Reuters) – Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 currently totals around 2.40 billion crowns ($340 million), including previously announced deferred revenue.
The World Health Organisation in August declared mpox a global public health emergency for the second time in two years after a variant of the virus called clade Ib spread from the Democratic Republic of Congo to neighbouring countries.
Bavarian Nordic is one of few firms that makes vaccine for mpox, a viral infection that causes flu-like symptoms and pus-filled lesions, and while usually mild, it can kill.
The committed orders for next year, combined with improved performance in our Travel Health business , and the launch of our chikungunya vaccine in Europe and the U.S. have set us up for another exciting and eventful year,” it said in a statement.
The company reported a small year-on-year drop in third-quarter sales but a swing to profit before interest and tax.
($1 = 7.0662 Danish crowns)
(Reporting by Anna Ringstrom, editing by Terje Solsvik)
